Premium
Phage therapy: Current status and perspectives
Author(s) -
Górski Andrzej,
Międzybrodzki Ryszard,
Węgrzyn Grzegorz,
JończykMatysiak Ewa,
Borysowski Jan,
WeberDąbrowska Beata
Publication year - 2020
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21593
Subject(s) - phage therapy , antimicrobial , status quo , antibiotics , clinical trial , drug , medicine , clinical practice , intensive care medicine , immunology , biology , microbiology and biotechnology , bacteriophage , pharmacology , political science , family medicine , genetics , gene , escherichia coli , law
The spread of antimicrobial resistant bacterial pathogens combined with the lack of new drug classes in the antibiotic pipeline causes a resurgence of the use of bacterial viruses (phages) to treat bacterial infections (phage therapy [PT]). There has been a substantial increase in patients subjected to this experimental therapy and emergence of new PT centers in Europe and the United States paralleled by one clinical trial completed in accord with good medical practice (GMP) requirements and a few others underway. What is more, evidence has been accumulating to suggest that phages can also exert anti‐inflammatory and immunomodulatory action which opens new pathways for the development of novel targets for PT. Here we present the status quo of the PT, recent regulatory, and clinical developments as well as new perspectives for its wider application in clinical medicine.